IPCA Laboratories Intrinsic Value
IPCA Laboratories (IPCALAB) median intrinsic value is ₹3525.40 from 9 valuation models (range ₹529–₹4407), vs current price ₹1762.70 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Analyse IPCA Laboratories shareholding analysis to track promoter, FII and institutional holdings.
IPCALAB Valuation Methods Summary — DCF, Graham Number & P/E
IPCA Laboratories intrinsic value across 9 models vs current price ₹1762.70 — upside/downside and value range per method. Read IPCALAB dividend history for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1171.28 | ₹937.02 - ₹1405.54 | -33.6% | EPS: ₹53.24, Sector P/E: 22x |
| Book Value Method | asset | ₹4406.75 | ₹3966.08 - ₹4847.43 | +150.0% | Book Value/Share: ₹3809.60, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹3525.40 | ₹3172.86 - ₹3877.94 | +100.0% | Revenue/Share: ₹3971.20, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹3525.40 | ₹3172.86 - ₹3877.94 | +100.0% | EBITDA: ₹2128.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹4406.75 | ₹3525.40 - ₹5288.10 | +150.0% | CF Growth: 7.5%, Discount: 15% |
| PEG Ratio Method | growth | ₹528.81 | ₹475.93 - ₹581.69 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹822.56 | ₹740.30 - ₹904.82 | -53.3% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹3525.40 | ₹3172.86 - ₹3877.94 | +100.0% | ROE: 12.9%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹2136.24 | ₹1922.62 - ₹2349.86 | +21.2% | EPS: ₹53.24, BVPS: ₹3809.60 |
IPCALAB Intrinsic Value vs Market Price — All Valuation Models
IPCA Laboratories fair value range ₹529–₹4407 vs current market price ₹1762.70 across 9 valuation models. For current market price and key ratios, visit IPCA Laboratories share price chart.
IPCALAB Intrinsic Value Analysis — Undervalued or Overvalued?
IPCA Laboratories median intrinsic value ₹3525.40, current price ₹1762.70 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of IPCALAB?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of IPCA Laboratories (IPCALAB) is ₹3525.40 (median value). With the current market price of ₹1762.70, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹528.81 to ₹4406.75, indicating ₹528.81 - ₹4406.75.
Is IPCALAB undervalued or overvalued?
Based on our multi-method analysis, IPCA Laboratories (IPCALAB) appears to be trading below calculated value by approximately 100.0%.
IPCALAB Financial Health — Key Ratios vs Industry Benchmarks
IPCA Laboratories financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 11.83 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 12.9% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 18.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.80x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
IPCALAB Cash Flow Quality — Operating & Free Cash Flow
IPCA Laboratories operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹1,142 Cr | ₹1,019 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹1,321 Cr | ₹886 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹945 Cr | ₹338 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹806 Cr | ₹444 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹856 Cr | ₹431 Cr | Positive Free Cash Flow | 8/10 |